⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

October 3, 2024

Figure S4 from FLT3/CD99 Bispecific Antibody–Based Nanoparticles for Acute Myeloid Leukemia

Atham Ali Alvin Phan Vijaya Vaikari Mincheol Park Mateusz Pospiech Ryan Chu Yiting Meng J. Andrew MacKay Houda Alachkar

View Full Paper

Ask AI

Bookmark

Share

Abstract

Figure S4 – qPCR analysis results for CDC25A, E2F1, CDKN2B, CDC20, and MYC in MV4-11 cells treated with with FLT3-A192, CD99-A192 and Co-Assembled CD99-A192 and FLT3-A192.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ali et al. (2024) studied this question.

synapsesocial.com/papers/68e55ee1e2b3180350efb8ee https://doi.org/10.1158/2767-9764.27157953

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Figure S3 from FLT3/CD99 Bispecific Antibody–Based Nanoparticles for Acute Myeloid Leukemia2024
2Figure S1 from FLT3/CD99 Bispecific Antibody–Based Nanoparticles for Acute Myeloid Leukemia2024
3Figure 7 from FLT3/CD99 Bispecific Antibody–Based Nanoparticles for Acute Myeloid Leukemia2024
4Figure 3 from FLT3/CD99 Bispecific Antibody–Based Nanoparticles for Acute Myeloid Leukemia2024
5Figure 4 from FLT3/CD99 Bispecific Antibody–Based Nanoparticles for Acute Myeloid Leukemia2024